Kilitch Drugs India Ltd has announced a total income of approximately INR 7.31 crores for Q4 FY26, as reported in their audited standalone and consolidated financial results. Notably, they plan to issue 1:1 bonus equity shares during the same quarter.

Kilitch Drugs reported a significant 51% year-over-year increase in Q4 EBITDA, reaching ₹221M, indicating improved profitability. The EBITDA margin also rose, climbing up by 0.9 percentage points to 24.7%. This positive development suggests Kilitch Drugs is enhancing its financial performance.

Kilitch Drugs India Ltd will reveal their Q4 FY26 and full-year audited financial results on May 15, 2026, following a board meeting. Trading activity has been suspended from April 1 to 48 hours after the announcement due to SEBI regulations.